Fig. 6: Effects of subcutaneous administration of Chol-HDO and complementary strand modification on exon-skipping efficiency and functions. | Nature Communications

Fig. 6: Effects of subcutaneous administration of Chol-HDO and complementary strand modification on exon-skipping efficiency and functions.

From: Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model

Fig. 6

a Detection of exon 23-skipped dystrophin mRNA in the indicated muscle of mdx mice after five weekly SC injections of Chol-HDO (11.88 μmol/kg) (n = 4–7 per group). b Serum CK levels in mice with five weekly SC injections of Chol-HDO (11.88 μmol/kg) (n = 4–9 per group). c Treadmill test (n = 4–7 per group) and (d) forelimb grip test (n = 4–13 per group) were also evaluated in mdx mice subcutaneously injected five times with Chol-HDO (11.88 μmol/kg). Data are presented as mean ± S.E.M (a–d) and were analyzed using one-way analysis of variance followed by Tukey’s Kramer tests (b–d). P-values are indicated. Source data are provided as a Source Data file.

Back to article page